Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
PremiumPress ReleasesFortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
20d ago
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
PremiumPress Releases
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
23d ago
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
PremiumPress Releases
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
23d ago
Fortress Biotech management to meet virtually with Roth MKM
PremiumThe FlyFortress Biotech management to meet virtually with Roth MKM
2M ago
Fortress Biotech files $50M mixed securities shelf
PremiumThe Fly
Fortress Biotech files $50M mixed securities shelf
2M ago
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
PremiumPress Releases
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
2M ago
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
PremiumPress ReleasesCheckpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
2M ago
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
PremiumPress Releases
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
3M ago
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
PremiumPress Releases
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100